Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $237.50 short put and a strike $232.50 long put offers a potential 23.46% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $237.50 by expiration. The full premium credit of $0.95 would be kept by the premium seller. The risk of $4.05 would be incurred if the stock dropped below the $232.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 66.71 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?
Fri, 22 Oct 2021 10:31:00 +0000
Merck (NYSE: MRK) and its partner, Ridgeback Biotherapeutics, hope to soon win U.S. Emergency Use Authorization (EUA) for the first COVID-19 pill. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss the potential impact of Merck's pill on COVID-19 antibody therapies.
What's in Store for Teladoc Health's (TDOC) Earnings in Q3?
Thu, 21 Oct 2021 17:35:05 +0000
Teladoc Health (TDOC) is likely to report a strong revenue outperformance for the third quarter, driven by broad-based momentum across its business and a sharp acceleration in visit-volume growth.
Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?
Thu, 21 Oct 2021 10:53:10 +0000
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.
Could This Be the Next Blockbuster Indication for Eli Lilly?
Thu, 21 Oct 2021 10:40:00 +0000
Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata.
4 Healthcare Stocks Selling for Way Less Than Analysts Think They’re Worth
Wed, 20 Oct 2021 17:23:00 +0000
Healthcare stocks are trailing the market since the start of the pandemic. Barron's looked for those at the biggest discounts to the average price targets among analysts.
Also on Market Tamer…
Follow Us on Facebook